📚 Part of the SGLT2 Inhibitors Trial Guide — every landmark trial in one place.
Series: Landmark Trials in Endocrinology & Metabolism | Study #3
Category: SGLT2 Inhibitors | Design: Multicentre, double-blind, placebo-controlled RCT | n: 17,160 | Follow-up: 4.2 years (median)
📋 Summary
Authors: Wiviott SD et al., for the DECLARE-TIMI 58 Investigators
Journal: N Engl J Med 2019;380:347–357 | DOI: 10.1056/NEJMoa1812389
A total of 17,160 patients with type 2 diabetes mellitus who had, or were at risk for, atherosclerotic cardiovascular disease were randomly assigned to receive dapagliflozin 10 mg once daily or placebo. Notably, 10,186 participants (59.4%) had multiple cardiovascular risk factors without established atherosclerotic cardiovascular disease, making DECLARE-TIMI 58 the most broadly representative of the three pivotal SGLT2 inhibitor cardiovascular outcomes trials. The trial prespecified two co-primary efficacy outcomes: 3-point MACE, comprising cardiovascular death, myocardial infarction, and ischaemic stroke; and a composite of cardiovascular death or hospitalisation for heart failure. Over a median follow-up of 4.2 years, dapagliflozin did not significantly reduce 3-point MACE (8.8% vs 9.4%; HR 0.93; 95% CI 0.84 to 1.03; p=0.17), but did significantly reduce the composite of cardiovascular death or hospitalisation for heart failure (4.9% vs 5.8%; HR 0.83; 95% CI 0.73 to 0.95; p=0.005). This composite benefit was driven entirely by a reduction in hospitalisation for heart failure (HR 0.73; 95% CI 0.61 to 0.88), as cardiovascular death did not differ significantly between groups (HR 0.98; 95% CI 0.82 to 1.17). A renal composite endpoint was also reduced with dapagliflozin (4.3% vs 5.6%; HR 0.76; 95% CI 0.67 to 0.87). Diabetic ketoacidosis occurred more frequently with dapagliflozin (0.3% vs 0.1%; p=0.02), as did serious genital infections (0.9% vs 0.1%; p<0.001).
📊 Key Findings
| Outcome | Dapagliflozin | Placebo | Effect Size |
|---|---|---|---|
| 3-point MACE (co-primary) | 8.8% | 9.4% | HR 0.93 (0.84–1.03) · p=0.17 · NS |
| CV death or HF hospitalisation (co-primary) | 4.9% | 5.8% | HR 0.83 (0.73–0.95) · p=0.005 |
| HF hospitalisation | see note | see note | HR 0.73 (0.61–0.88) · 27% RRR |
| Cardiovascular death | see note | see note | HR 0.98 (0.82–1.17) · NS |
| All-cause mortality | 6.2% | 6.6% | HR 0.93 (0.82–1.04) · NS |
| Renal composite | 4.3% | 5.6% | HR 0.76 (0.67–0.87) |
| Diabetic ketoacidosis | 0.3% | 0.1% | p=0.02 · Safety signal |
| Absolute risk reduction (CV death or HF hospitalisation) | 0.9% over 4.2 years | NNT approximately 111 | |
DECLARE-TIMI 58
RCT · type 2 diabetes · 4.2 years
Dapagliflozin reduced heart failure hospitalisation and slowed renal disease progression across a broad type 2 diabetes population, including patients without established cardiovascular disease. It did not significantly reduce 3-point MACE.
💬 Expert Commentary
DECLARE-TIMI 58 occupies a distinctive position within the SGLT2 inhibitor CVOT landscape, not because of a compelling mortality signal, but because of what the trial design revealed about the conditions under which cardiovascular protection from this drug class is most likely to be observed. With nearly 60% of participants enrolled on the basis of cardiovascular risk factors alone rather than established atherosclerotic cardiovascular disease, the trial enrolled a population substantially closer to the broad type 2 diabetes population encountered in routine endocrine and general medical practice. The failure of 3-point MACE to reach significance in this lower-risk cohort is not a negative result in isolation. It is a mechanistically informative one. It reinforces the inference, already suggested by subgroup analyses from EMPA-REG OUTCOME and CANVAS, that SGLT2 inhibitors reduce cardiovascular events predominantly through heart failure and renal pathways rather than through anti-atherosclerotic mechanisms, and that this benefit is most pronounced in patients with an elevated baseline heart failure risk or existing left ventricular dysfunction.
The 27% reduction in heart failure hospitalisation, achieved in a population with a lower event rate than preceding trials, is clinically important. It extended the heart failure hospitalisation benefit of SGLT2 inhibition into a primary prevention context and strengthened the signal sufficiently to support subsequent dedicated heart failure outcome trials in both diabetic and non-diabetic populations. The renal composite reduction of 24% added further consistency to the emerging cardiorenal protection profile of the class. The absolute risk reduction for the combined cardiovascular death and heart failure hospitalisation endpoint was 0.9%, corresponding to an NNT of approximately 111 over 4.2 years, which reflects the lower event rate inherent to a broader-risk population and should be considered in the context of individual patient risk profiling when initiating therapy. The diabetic ketoacidosis signal, while small in absolute terms, warrants clinical attention, particularly in patients who fast perioperatively or who follow significant carbohydrate restriction.
Limitations: The failure of 3-point MACE to reach significance may reflect insufficient statistical power within the lower-risk primary prevention subgroup rather than a true absence of effect. The two co-primary endpoints introduce multiplicity considerations in the interpretation of efficacy findings. Cardiovascular death was not individually reduced, in contrast to findings from EMPA-REG OUTCOME. The study was industry-sponsored by AstraZeneca.
🔑 BOTTOM LINE
DECLARE-TIMI 58 demonstrated that dapagliflozin reduces hospitalisation for heart failure and slows renal disease progression across a broad type 2 diabetes population that includes patients without established cardiovascular disease, confirming that the cardiorenal benefits of SGLT2 inhibition extend well beyond the high-risk secondary prevention context in which they were first identified.
⭐ Clinical Impact Rating: ●●●●○ Practice-changing in broader population